Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Lymphoma × orelabrutinib × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, B-Cell, Marginal Zone 10 Lymphoma, Mantle-Cell 6 Lymphoma, Large B-Cell, Diffuse 4 Leukemia, Lymphocytic, Chronic, B-Cell 2 Recurrence 1 Lymphoma, Follicular 1 Lymphoma, B-Cell 1 Lymphoma 1

Interventions

Cyclophosphamide 214 Rituximab 198 Etoposide 124 Filgrastim 101 Vincristine 98 Doxorubicin 91 Cytarabine 82 Prednisone 77 Radiotherapy 73 Methotrexate 70 Melphalan 65 fludarabine phosphate 64 Peripheral Blood Stem Cell Transplantation 64 Busulfan 52 Dexamethasone 45 Carmustine 42 Tacrolimus 39 Mycophenolic Acid 38 fludarabine 37 Granulocyte Colony-Stimulating Factor 37 Ifosfamide 35 Antilymphocyte Serum 35 Whole-Body Irradiation 31 sargramostim 29 Gemcitabine 28 Bortezomib 28 Cyclosporine 27 Methylprednisolone 25 Bendamustine Hydrochloride 25 Cisplatin 23

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07206264 2025-10-03

ADAPT-MCL

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting

Lymphoma, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡